AI PRICE FORECAST
VRTX Stock Forecast & AI Price Prediction
Vertex Pharmaceuticals · Healthcare · Biotechnology
VRTX live signal snapshot
VRTX last traded at $547.03, down 0.16% on the session, trading 3.8% below its 52-week high of $568.67 and 32.7% above its 52-week low of $412.27. Stock Pulse 247's AI model currently rates VRTX a BUY, at 86% model confidence. Short-term momentum is constructive: the 5-, 10- and 20-day moving averages are stacked upward and price is holding above the 50-day average. The model's one-month path points toward roughly $567.68 (3.8% from here).
On the 14-day relative strength index, VRTX reads 60.2, showing buyers in control without the stretch of an overbought reading. Its MACD line is above its signal line with a positive histogram (1.46) — upward momentum is accelerating. With the 50-day average at $523.04, 8.4% over the 200-day's $482.70, the longer-term trend structure remains positive.
The average 12-month target from 28 Wall Street analysts is $595.36 (range $350.00–$725.00) — 8.8% upside from where VRTX trades now. The current recommendation trend leans bullish: 26 Buy/Strong Buy ratings vs 1 Sell/Strong Sell (and 5 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive VRTX dashboard for numbers updated throughout today's session.
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company in the healthcare sector, headquartered in Boston, MA, United States. Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. It has a market value of about $138.7 billion and roughly 6,400 full-time employees. With a beta of 0.28, the stock has historically moved less than the overall market.
VRTX performance vs. the market
Year to date, VRTX has gained 20.7%, ahead of the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). On a one-year view it is up 29.9%, 18.4 points better than the S&P 500. The last month (+12.7%) continues the three-month advance (+5.9%).
| Period | VRTX | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +12.7% | +11.4% | −2.3% |
| 3 months | +5.9% | +12.2% | −2.3% |
| Year to date | +20.7% | +22.1% | +11.4% |
| 1 year | +29.9% | +28.3% | +11.5% |
Vertex Pharmaceuticals financials at a glance
In the quarter ended Sep 30, 2026, Vertex Pharmaceuticals reported revenue of $3.4 billion and net income of $654 million (a 19.0% net margin). Revenue was up 11.8% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 35.2 on trailing earnings of $15.54 per share. Trailing free cash flow was $2.3 billion, and total debt equals 31% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $3.4B | $654M |
| Jun 30, 2026 | $3.3B | $1.1B |
| Mar 31, 2026 | $3.0B | $1.0B |
| Dec 31, 2025 | $3.2B | $1.2B |
VRTX vs. its peers
Against 5 of its largest healthcare peers, VRTX's +20.7% year-to-date return beats 0 of them. The strongest of the group this year is Merck & Co. (MRK, +39.8%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| Vertex Pharmaceuticals (VRTX) | $547.03 | +20.7% | 35.2 | BUY |
| Regeneron Pharmaceuticals (REGN) | $959.41 | +24.3% | 21.2 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
| Johnson & Johnson (JNJ) | $280.41 | +35.5% | 42.6 | BUY |
| AbbVie (ABBV) | $294.98 | +29.1% | 50.7 | BUY |
| Merck & Co. (MRK) | $147.18 | +39.8% | 148.7 | HOLD |
VRTX stock: common questions
What is the VRTX stock price target?
28 Wall Street analysts put the average 12-month target at $595.36, in a range of $350.00–$725.00, versus a recent price of $547.03. Stock Pulse 247's model projects about $567.68 over the next month.
Is VRTX a buy right now?
Our AI model currently rates VRTX a BUY at 86% confidence. Among analysts, 26 rate it Buy or Strong Buy, 5 Hold and 1 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has VRTX stock performed this year?
Year to date, VRTX has gained 20.7%, ahead of the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). On a one-year view it is up 29.9%, 18.4 points better than the S&P 500. The last month (+12.7%) continues the three-month advance (+5.9%).
What is VRTX's 52-week high and low?
VRTX has traded between $412.27 and $568.67 over the past 52 weeks; at $547.03 it is 3.8% below its 52-week high of $568.67 and 32.7% above its 52-week low of $412.27.
What sector is VRTX in, and who are its peers?
VRTX is in the healthcare sector (biotechnology). Its largest peers on Stock Pulse 247 include Regeneron Pharmaceuticals (REGN), Eli Lilly and (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV).
How accurate is the VRTX forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines VRTX's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.